Compare drug alternatives

Vyepti® Alternatives

Vyepti®(eptinezumab)
Emgality®(galcanezumab-gnlm)
Prescription Only
Vypeti is a prescription medication used for migraine prevention. It is administered as an intravenous infusion four times a year. The most common reported side effects were...
Prescription Only
Emgality is a medication that can be self-administered once a month by injecting it subcutaneously under the skin. It is used for migraine prevention in adults and can also be...
Dosage & Administration
Administration
Intravenous Infusion. Learn more.
Subcutaneous. Learn more.
Dosing
Recommended dosage is 100 mg as an intravenous infusion over approximately 30 minutes every 3 months. Some patients may benefit from a dosage of 300 mg . Learn more.
Migraine: 240 mg loading dose (120 mg x 2) followed by 120 mg monthly. . Learn more.
Latin Shorthand
100 mg IV infusion over ~30 mins q3mo. Some patients may benefit from 300 mg dosage.. Learn more.
240 mg LD (120 mg x 2) then 120 mg/mo.. Learn more.
Financial Assistance
Out-Of-Pocket Costs With Copay Card
Annual Cap
$200 per infusion administration fee. Learn more.
$4900. Learn more.
Assistance Expiration
12 months. Learn more.
Generics
No lower-cost generic available
No lower-cost generic available
Physician Advisory
Adverse Reactions
The most common adverse reactions (≥2% and 2% or greater than placebo) were nasopharyngitis and hypersensitivity.. Learn more.
The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in EMGALITY clinical studies were injection site reactions. . Learn more.
Mechanism of Actions (MoA)
CGRP Antagonist. Learn more.
CGRP Antagonist. Learn more.
Special Populations
Is it safe to use VYEPTI during pregnancy?

There is no adequate data on the developmental risks associated with the use of VYEPTI in pregnant women. No adverse developmental effects were observed in animals receiving eptinezumab-jjmr at doses greater than those used clinically. Women with migraine may be at increased risk of preeclampsia and gestational hypertension during pregnancy, according to published data. It is important to discuss with your healthcare provider if VYEPTI is necessary during pregnancy.

Are there any risks to the fetus if the mother receives VYEPTI?

Animal studies have shown no adverse effects on embryofetal development when eptinezumab-jjmr was administered to pregnant animals at doses greater than those used clinically. However, there is no adequate data on the developmental risks associated with the use of VYEPTI in pregnant women. The estimated background risk of major birth defects and miscarriages in clinically recognized pregnancies in the U.S. general population is 2%-4% and 15%-20%, respectively.

Is it safe to breastfeed while using VYEPTI?

There are no data on the presence of eptinezumab-jjmr in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for VYEPTI and any potential adverse effects on the breastfed infant from VYEPTI or from the underlying maternal condition. It is important to discuss with your healthcare provider if VYEPTI is necessary while breastfeeding.

Is VYEPTI safe for use in pediatric patients?

Safety and effectiveness in pediatric patients have not been established for VYEPTI. It is important to discuss with your healthcare provider if VYEPTI is necessary for pediatric patients.

Is VYEPTI safe for use in geriatric patients?

Clinical studies of VYEPTI did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. Dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. It is important to discuss with your healthcare provider if VYEPTI is necessary for geriatric patients.

What is the Pregnancy Exposure Registry for EMGALITY?

The Pregnancy Exposure Registry is a program that monitors pregnancy outcomes in women who have been exposed to EMGALITY during pregnancy. It is designed to collect information on any potential risks to the developing fetus.

How can pregnant women enroll in the Pregnancy Exposure Registry?

Pregnant women can enroll in the registry by calling 1-833-464-4724 or by contacting the company at www.migrainepregnancyregistry.com.

What is the estimated risk of major birth defects and miscarriage in the general population and among women with migraine?

The estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%-4% and 15%-20%, respectively, in the general population. The estimated rate of major birth defects (2.2%-2.9%) and miscarriage (17%) among deliveries to women with migraine are similar to rates reported in women without migraine.

Are there any known risks associated with the use of EMGALITY during pregnancy?

There are no adequate data on the developmental risk associated with the use of EMGALITY in pregnant women. However, animal studies have shown that administration of galcanezumab-gnlm to rats and rabbits during the period of organogenesis or to rats throughout pregnancy and lactation at plasma exposures greater than that expected clinically did not result in adverse effects on development.

Can EMGALITY be used during lactation?

There are no data on the presence of galcanezumab-gnlm in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for EMGALITY and any potential adverse effects on the breastfed infant from EMGALITY or from the underlying maternal condition.

Is EMGALITY safe for pediatric use?

Safety and effectiveness in pediatric patients have not been established.

Is there any difference in the response to EMGALITY in geriatric patients compared to younger patients?

Clinical studies of EMGALITY did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients.